1
|
Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, Wipplinger D, Milanov R, Strassl I, Stiefel O, Machherndl-Spandl S, Petzer A, Weltermann A, Clausen J. Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion. Cytotherapy 2024; 26:490-497. [PMID: 38385908 DOI: 10.1016/j.jcyt.2024.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 01/25/2024] [Accepted: 02/08/2024] [Indexed: 02/23/2024]
Abstract
BACKGROUND AIMS Cyclosporin A (CsA) remains a major component of immunosuppressive regimens applied in allogeneic hematopoietic stem cell transplantation (HSCT). The impact of CsA trough levels during the first weeks after HSCT has not yet been investigated specifically in anti-T-lymphocyte globulin (ATLG)-based HSCT from matched related and unrelated donors. METHODS To address this issue, we have retrospectively examined 307 consecutive matched related (n = 145) and unrelated (n = 162) HSCTs, using peripheral blood stem cells or bone marrow. HSCTs for active, uncontrolled malignancies were excluded. The initial three weeks' average mean CsA trough levels were analyzed in landmark and multi-state models, using a cut-off of 200 ng/mL. RESULTS CsA levels >200 ng/mL were associated with a reduced risk of acute graft-versus-host disease (GVHD) grade 3-4 at the first-week landmark (subdistribution hazard ratio [SHR] 0.59, P = 0.03) and the second-week landmark (SHR 0.48, P = 0.004), whereas there was no impact at the third-week landmark (HR 0.87, P = 0.69). This was supported by a multi-state model, in which week 1 (hazard ratio [HR] 0.53, P = 0.006) and week 2 (HR 0.48, P = 0.003), but not week 3 (HR 0.80, P = 0.44) CsA levels >200 ng/mL were associated with a reduced acute GVHD 3-4 risk. Relapse incidence was not significantly affected by week 1 through 3 CsA levels. Despite ATLG's inherent GVHD-preventive properties, week 1 CsA trough levels >200 ng/mL following ATLG-based HSCT (n = 220) were associated with a significantly reduced risk of non-relapse mortality (SHR 0.52, P = 0.02) and improved overall survival (HR 0.61, P = 0.02). CONCLUSIONS Our findings emphasize the continuing importance of ensuring CsA levels ≥200 ng/mL immediately post-transplant in the setting of ATLG-based HSCT.
Collapse
Affiliation(s)
- Alexander Nikoloudis
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria.
| | - Veronika Buxhofer-Ausch
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Christoph Aichinger
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria
| | - Michaela Binder
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria
| | - Petra Hasengruber
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria
| | - Emine Kaynak
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria
| | - Dagmar Wipplinger
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria
| | - Robert Milanov
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria
| | - Irene Strassl
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Olga Stiefel
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Sigrid Machherndl-Spandl
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Andreas Petzer
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Ansgar Weltermann
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Johannes Clausen
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| |
Collapse
|
2
|
Strassl I, Nikoloudis A, Machherndl-Spandl S, Buxhofer-Ausch V, Binder M, Wipplinger D, Stiefel O, Kaynak E, Milanov R, Aichinger C, Nocker S, Bauer T, Kreissl S, Girschikofsky M, Petzer A, Weltermann A, Clausen J. Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options-A Single-Center Experience. Cancers (Basel) 2023; 15:5738. [PMID: 38136284 PMCID: PMC10742138 DOI: 10.3390/cancers15245738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 12/02/2023] [Accepted: 12/05/2023] [Indexed: 12/24/2023] Open
Abstract
BACKGROUND Despite major treatment advances, multiple myeloma remains incurable. The outcome of patients who are refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies is poor, and improved treatment strategies for this difficult-to-treat patient population are an unmet medical need. METHODS This retrospective, unicentric analysis included 38 patients with relapsed/refractory multiple myeloma or plasma cell leukemia who underwent allogeneic stem cell transplantation (allo-HSCT) between 2013 and 2022. Survival outcomes, relapse incidence, and non-relapse mortality were calculated according to remission status, date of allo-HSCT, cytogenetic risk status, timing, and number of previous autologous HSCTs. RESULTS The median PFS was 13.6 months (95% CI, 7.7-30.4) and the median OS was 51.4 months (95% CI, 23.5-NA) in the overall cohort. The cumulative incidence of relapse at 3 years was 57%, and non-relapse mortality was 16%. The median PFS and OS were significantly longer in patients with very good partial remission (VGPR) or better compared to patients with less than VGPR at the time of allo-HSCT (mPFS 29.7 months (95% CI, 13.7-NA) vs. 6.5 months (95% CI, 2.6-17.0); p = 0.009 and mOS not reached vs. 18.6 months (95% CI, 7.0-NA); p = 0.006). CONCLUSION For selected patients, allo-HSCT may result in favorable overall survival, in part by providing an appropriate hemato-immunological basis for subsequent therapies.
Collapse
Affiliation(s)
- Irene Strassl
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| | - Alexander Nikoloudis
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| | - Sigrid Machherndl-Spandl
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| | - Veronika Buxhofer-Ausch
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| | - Michaela Binder
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
| | - Dagmar Wipplinger
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
| | - Olga Stiefel
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| | - Emine Kaynak
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
| | - Robert Milanov
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
| | - Christoph Aichinger
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
| | - Stefanie Nocker
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| | - Thomas Bauer
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| | - Stefanie Kreissl
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
| | - Michael Girschikofsky
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
| | - Andreas Petzer
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| | - Ansgar Weltermann
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| | - Johannes Clausen
- Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz, Austria; (A.N.); (S.M.-S.); (V.B.-A.); (D.W.); (O.S.); (E.K.); (R.M.); (C.A.); (S.N.); (T.B.); (S.K.); (M.G.); (A.P.); (A.W.); (J.C.)
- Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria
| |
Collapse
|
3
|
Nikoloudis A, Neumann IJ, Buxhofer-Ausch V, Machherndl-Spandl S, Binder M, Kaynak E, Milanov R, Nocker S, Stiefel O, Strassl I, Wipplinger D, Moyses M, Kerschner H, Apfalter P, Girschikofsky M, Petzer A, Weltermann A, Clausen J. Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients-A Retrospective Single-Center Analysis. Vaccines (Basel) 2023; 11:1534. [PMID: 37896938 PMCID: PMC10611175 DOI: 10.3390/vaccines11101534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 09/20/2023] [Accepted: 09/27/2023] [Indexed: 10/29/2023] Open
Abstract
(1) Background: mRNA COVID-19 vaccines are effective but show varied efficacy in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HSCT) recipients. (2) Methods: A retrospective study on 167 HSCT recipients assessed humoral response to two mRNA vaccine doses, using the manufacturer cut-off of ≥7.1 BAU/mL, and examined factors affecting non-response. (3) Results: Twenty-two percent of HSCT recipients failed humoral response. Non-responders received the first vaccine a median of 10.2 (2.5-88.9) months post-HSCT versus 35.3 (3.0-215.0) months for responders (p < 0.001). Higher CD19 (B cell) counts favored vaccination response (adjusted odds ratio (aOR) 3.3 per 100 B-cells/microliters, p < 0.001), while ongoing mycophenolate mofetil (MMF) immunosuppression hindered it (aOR 0.04, p < 0.001). By multivariable analysis, the time from transplant to first vaccine did not remain a significant risk factor. A total of 92% of non-responders received a third mRNA dose, achieving additional 77% seroconversion. Non-converters mostly received a fourth dose, with an additional 50% success. Overall, a cumulative seroconversion rate of 93% was achieved after up to four doses. (4) Conclusion: mRNA vaccines are promising for HSCT recipients as early as 3 months post-HSCT. A majority seroconverted after four doses. MMF usage and low B cell counts are risk factors for non-response.
Collapse
Affiliation(s)
- Alexander Nikoloudis
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | | | - Veronika Buxhofer-Ausch
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Sigrid Machherndl-Spandl
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Michaela Binder
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Emine Kaynak
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Robert Milanov
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Stefanie Nocker
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Olga Stiefel
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Irene Strassl
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Dagmar Wipplinger
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Margarete Moyses
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Heidrun Kerschner
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
- Institute for Hygiene, Microbiology and Tropical Medicine, Ordensklinikum, Linz, Austria
| | - Petra Apfalter
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
- Institute for Hygiene, Microbiology and Tropical Medicine, Ordensklinikum, Linz, Austria
| | - Michael Girschikofsky
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Andreas Petzer
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Ansgar Weltermann
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| | - Johannes Clausen
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Ordensklinikum Linz—Elisabethinen, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
- Interdisciplinary Center for Infectious Medicine and Microbiology, Linz, Austria
| |
Collapse
|
4
|
Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, Wipplinger D, Milanov R, Strassl I, Stiefel O, Machherndl-Spandl S, Petzer A, Weltermann A, Clausen J. Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation. Cells 2023; 12:1831. [PMID: 37508496 PMCID: PMC10378354 DOI: 10.3390/cells12141831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 07/07/2023] [Accepted: 07/10/2023] [Indexed: 07/30/2023] Open
Abstract
Background: In allogeneic hematopoietic stem cell transplantation (HSCT), Anti-T-Lymphocyte Globulin (ATLG) may be used for the prevention of severe graft-versus-host disease (GVHD). ATLG targets both the recipient's lymphocytes and those transferred with the graft. Assuming an inverse relation between the recipient's absolute lymphocyte count (ALC) and exposure of remaining ATLG to the graft, we aim to evaluate the impact of the recipient's ALC before the first ATLG administration on the benefits (prevention of GVHD and GVHD-associated mortality) and potential risks (increased relapse incidence) associated with ATLG. Methods: In recipients of HLA-matched, ATLG-based HSCT (n = 311), we assessed the incidence of acute GVHD, GVHD-related mortality and relapse, as well as other transplant-related outcomes, in relation to the respective ALC (divided into tertiles) before ATLG. Results: The top-tertile ALC group had a significantly increased risk of aGVHD (subhazard ratio (sHR) 1.81; [CI 95%; 1.14-2.88]; p = 0.01) and aGVHD-associated mortality (sHR 1.81; [CI 95%; 1.03-3.19]; p = 0.04). At the highest ATLG dose level (≥45 mg/kg), recipients with lowest-tertile ALC had a trend towards increased relapse incidence (sHR 4.19; [CI 95%; 0.99-17.7]; p = 0.05, n = 32). Conclusions: ATLG dosing based on the recipient's ALC may be required for an optimal balance between GVHD suppression and relapse prevention.
Collapse
Affiliation(s)
- Alexander Nikoloudis
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
| | - Veronika Buxhofer-Ausch
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
| | - Christoph Aichinger
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
| | - Michaela Binder
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
| | - Petra Hasengruber
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
| | - Emine Kaynak
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
| | - Dagmar Wipplinger
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
| | - Robert Milanov
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
| | - Irene Strassl
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
| | - Olga Stiefel
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
| | - Sigrid Machherndl-Spandl
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
| | - Andreas Petzer
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
| | - Ansgar Weltermann
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
| | - Johannes Clausen
- Ordensklinikum Linz-Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, 4020 Linz, Austria
- Medical Faculty, Johannes Kepler University, 4020 Linz, Austria
| |
Collapse
|
5
|
Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, Wipplinger D, Milanov R, Strassl I, Stiefel O, Machherndl-Spandl S, Petzer A, Weltermann A, Clausen J. Adverse impact of a high CD4/CD8 ratio in the allograft may be overcome by methotrexate- but not mycophenolate- or posttransplant cyclophosphamide-based graft versus host disease prophylaxis. Eur J Haematol 2023; 110:715-724. [PMID: 36941654 DOI: 10.1111/ejh.13956] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 03/11/2023] [Accepted: 03/16/2023] [Indexed: 03/23/2023]
Abstract
INTRODUCTION A high CD4/CD8 T cell ratio in hematopoietic stem cell transplant (HSCT) allografts was observed to predict graft-versus-host disease (GVHD) and non-relapse mortality (NRM) but has not been comparatively examined in settings of various GVHD-prophylaxis regimens. METHODS This retrospective monocentric study included all consecutive HSCT performed with peripheral blood stem cells (PBSC) between January 2000 and June 2021. The impact of the graft CD4/CD8 ratio was analyzed in three cohorts with different GVHD-prophylaxis platforms. RESULTS In the cyclosporine/mycophenolate-mofetil (CSA/MMF) cohort (n = 294, HLA-matched HSCT), a high (> 75th percentile) CD4/CD8 ratio was associated with increased overall mortality (HR 1.56; P=0.01), increased NRM (HR 1.85; P=0.01) and GVHD-associated mortality (HR 2.13; P=0.005). In the post-transplant cyclophosphamide (PTCy)/tacrolimus/MMF cohort (n = 113, haploidentical-related or mismatched-unrelated HSCT), a high CD4/CD8 ratio was associated with increased overall mortality (HR 2.07; P=0.04) and aGVHD3-4 (HR 2.24; P=0.02). By contrast, in the CSA/methotrexate (CSA/MTX) cohort (n = 185, HLA-matched HSCT) the CD4/CD8 ratio had no significant impact on any of the investigated endpoints. CONCLUSION A high CD4/CD8 ratio in the allograft has an adverse impact on GVHD and survival in CSA/MMF- and PTCy-based HSCT, while MTX-based prophylaxis may largely alleviate this important risk factor.
Collapse
Affiliation(s)
- A Nikoloudis
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
- Johannes Kepler University, Medical Faculty, Linz, Austria
| | - V Buxhofer-Ausch
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
- Johannes Kepler University, Medical Faculty, Linz, Austria
| | - C Aichinger
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
| | - M Binder
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
| | - P Hasengruber
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
| | - E Kaynak
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
| | - D Wipplinger
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
| | - R Milanov
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
| | - I Strassl
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
- Johannes Kepler University, Medical Faculty, Linz, Austria
| | - O Stiefel
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
- Johannes Kepler University, Medical Faculty, Linz, Austria
| | - S Machherndl-Spandl
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
- Johannes Kepler University, Medical Faculty, Linz, Austria
| | - A Petzer
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
- Johannes Kepler University, Medical Faculty, Linz, Austria
| | - A Weltermann
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
- Johannes Kepler University, Medical Faculty, Linz, Austria
| | - J Clausen
- Ordensklinikum Linz - Elisabethinen, Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Linz, Austria
- Johannes Kepler University, Medical Faculty, Linz, Austria
| |
Collapse
|
6
|
Abdallah N, Smith A, Geyer S, Binder M, Greipp P, Kapoor P, Dispenzieri A, Gertz M, Baughn L, Lacy M, Hayman S, Buadi F, Dingli D, Hwa Y, Lin Y, Kourelis T, Warsame R, Kyle R, Rajkumar S, Kumar S. 639P Conditional survival in MM and impact of prognostic factors over time. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
7
|
Stintzing S, Dechow T, Vehling-Kaiser U, Lorenzen S, Hannig CV, Schwaner I, Fischer von Weikersthal L, Puchtler G, Binder M, Held S, Heinrich K, Heinemann V. 424P Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer: The phase-II FIRE-6 (AIO KRK-0118). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
8
|
Schultheiß C, Claaß L, Scholz R, Paschold L, Simnica D, Heinemann V, Stintzing S, Binder M. 1688P Selection of PD-L1 escape variants in microsatellite stable metastatic colorectal cancer on avelumab treatment. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Machherndl-Spandl S, Vockenhuber T, Binder M, Weltermann A, Apfalter P, Lass-Flörl C, Girschikofsky M. Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia. Leuk Lymphoma 2022; 63:2330-2335. [DOI: 10.1080/10428194.2022.2068006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Sigrid Machherndl-Spandl
- Department of Internal Medicine I (Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Thomas Vockenhuber
- Department of Internal Medicine I (Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Michaela Binder
- Department of Internal Medicine I (Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Ansgar Weltermann
- Department of Internal Medicine I (Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Petra Apfalter
- Institute of Hygiene, Microbiology and Tropical Medicine and analyse BioLab, National Reference Centre for Antimicrobial Resistance, IZIM – Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Cornelia Lass-Flörl
- Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
| | - Michael Girschikofsky
- Department of Internal Medicine I (Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria
| |
Collapse
|
10
|
Loske J, Röhmel J, Lukassen S, Stricker S, Magalhães VG, Liebig J, Chua RL, Thürmann L, Messingschlager M, Seegebarth A, Timmermann B, Klages S, Ralser M, Sawitzki B, Sander LE, Corman VM, Conrad C, Laudi S, Binder M, Trump S, Eils R, Mall MA, Lehmann I. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat Biotechnol 2022; 40:319-324. [PMID: 34408314 DOI: 10.1038/s41587-021-01037-9] [Citation(s) in RCA: 167] [Impact Index Per Article: 83.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 07/28/2021] [Indexed: 12/20/2022]
Abstract
Children have reduced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates and a substantially lower risk for developing severe coronavirus disease 2019 compared with adults. However, the molecular mechanisms underlying protection in younger age groups remain unknown. Here we characterize the single-cell transcriptional landscape in the upper airways of SARS-CoV-2-negative (n = 18) and age-matched SARS-CoV-2-positive (n = 24) children and corresponding samples from adults (n = 44), covering an age range of 4 weeks to 77 years. Children displayed higher basal expression of relevant pattern recognition receptors such as MDA5 (IFIH1) and RIG-I (DDX58) in upper airway epithelial cells, macrophages and dendritic cells, resulting in stronger innate antiviral responses upon SARS-CoV-2 infection than in adults. We further detected distinct immune cell subpopulations including KLRC1 (NKG2A)+ cytotoxic T cells and a CD8+ T cell population with a memory phenotype occurring predominantly in children. Our study provides evidence that the airway immune cells of children are primed for virus sensing, resulting in a stronger early innate antiviral response to SARS-CoV-2 infection than in adults.
Collapse
Affiliation(s)
- J Loske
- Molecular Epidemiology Unit, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - J Röhmel
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu, Berlin, Germany
| | - S Lukassen
- Center for Digital Health, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - S Stricker
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu, Berlin, Germany
| | - V G Magalhães
- Research group "Dynamics of Early Viral Infection and the Innate Antiviral Response", division F170, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - J Liebig
- Center for Digital Health, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - R L Chua
- Center for Digital Health, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - L Thürmann
- Molecular Epidemiology Unit, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - M Messingschlager
- Molecular Epidemiology Unit, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - A Seegebarth
- Molecular Epidemiology Unit, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - B Timmermann
- Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - S Klages
- Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - M Ralser
- Institute of Biochemistry, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - B Sawitzki
- Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | - L E Sander
- Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
- German Center for Lung Research (DZL), associated partner, Berlin, Germany
| | - V M Corman
- Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
- German Centre for Infection Research (DZIF), Associated Partner Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - C Conrad
- Center for Digital Health, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - S Laudi
- Department of Anesthesiology and Intensive Care, University Hospital Leipzig, Leipzig, Germany
| | - M Binder
- Research group "Dynamics of Early Viral Infection and the Innate Antiviral Response", division F170, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - S Trump
- Molecular Epidemiology Unit, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - R Eils
- Center for Digital Health, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany.
- German Center for Lung Research (DZL), associated partner, Berlin, Germany.
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
| | - M A Mall
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu, Berlin, Germany
- German Center for Lung Research (DZL), associated partner, Berlin, Germany
| | - I Lehmann
- Molecular Epidemiology Unit, Berlin Institute of Health at the Charité - Universitätsmedizin Berlin, Berlin, Germany
- German Center for Lung Research (DZL), associated partner, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| |
Collapse
|
11
|
You J, Bachmann C, Belardi V, Binder M, Bowden D, Calabrò G, Fanelli P, Fursdon M, Garkusha I, Gerashchenko S, Hunger K, de Luca R, Makhlai V, Mantel N, Maviglia F, Müller AV, Nemati N, Roberts J, Vivio F, Vizvary Z, Zhang K. Limiters for DEMO wall protection: Initial design concepts & technology options. Fusion Engineering and Design 2022. [DOI: 10.1016/j.fusengdes.2021.112988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
12
|
Stein A, Paschold L, Tintelnot J, Goekkurt E, Thuss-Patience P, Lorenzen S, Ettrich T, Knorrenschild JR, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hinke A, Hegewisch Becker S, Binder M. LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2134] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
13
|
Nikoloudis A, Wagner H, Machherndl-Spandl S, Buxhofer-Ausch V, Strassl I, Stiefel O, Wipplinger D, Milanov R, Kaynak E, Hasengruber P, Binder M, Weltermann A, Petzer A, Wolf D, Nachbaur D, Clausen J. Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients. Transplant Cell Ther 2021; 27:686.e1-686.e9. [PMID: 33991724 DOI: 10.1016/j.jtct.2021.04.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Revised: 04/23/2021] [Accepted: 04/29/2021] [Indexed: 11/29/2022]
Abstract
Although the risk for nonrelapse mortality (NRM) associated with early cytomegalovirus (CMV) reactivation (CMVR) after allogeneic hematopoietic stem cell transplantation (HSCT) is well established, debate is ongoing on whether CMVR may reduce the risk of primary disease relapse. The aim of this study was to evaluate relapse protection following early CMV reactivation after HSCT in the context of the recipient HLA-C killer cell immunoglobulin-like receptor ligands (KIRLs). In this retrospective bicentric study, 406 matched related or unrelated donor transplantations for acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) were stratified by HLA-C KIRL group (homozygous versus heterozygous) and analyzed separately for the impact of early CMVR on the cumulative incidences of relapse, NRM, and acute and chronic graft-versus-host-disease (GVHD) using landmark and multistate analyses. By landmark analysis of patients alive and relapse-free at 45 days post-HSCT, HLA-C KIRL homozygous recipients (C1/1 or C2/2) had a lower risk of subsequent relapse if CMVR occurred before this landmark (subhazard ratio [sHR], 0.36; P = .002). In contrast, in HLA-C KIRL heterozygous (C1/2) recipients, early CMVR had no impact on subsequent relapse (sHR, 0.88; P = .63). NRM (sHR, 3.31; P < .001) and grade III-IV acute GVHD (sHR, 2.60; P = .04) were significantly increased after early CMVR in the homozygous cohort, but not in the heterozygous cohort (NRM: sHR, 1.23; P = .53; grade III-IV acute GVHD: sHR, 1.40; P = .50). Multivariable landmark analyses and a multistate model confirmed the limitation of the relapse-protective effect of early CMVR to the homozygous cohort. Chronic GVHD and overall survival were not influenced in neither cohort. An antileukemic effect of early CMVR after HSCT for AML/MDS was significant but strictly limited to recipients homozygous for HLA-C KIRL. However, particularly in this cohort, CMVR had an adverse impact on aGVHD and NRM.
Collapse
Affiliation(s)
- Alexander Nikoloudis
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria.
| | - Helga Wagner
- Department of Applied Statistics: Medical Statistics and Biometry and Competence Center for Clinical Studies, Johannes Kepler University, Linz, Austria
| | - Sigrid Machherndl-Spandl
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Veronika Buxhofer-Ausch
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Irene Strassl
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Olga Stiefel
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Dagmar Wipplinger
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Robert Milanov
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Emine Kaynak
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Petra Hasengruber
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Michaela Binder
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Ansgar Weltermann
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| | - Andreas Petzer
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
| | - Dominik Wolf
- University Hospital of Internal Medicine V, Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria
| | - David Nachbaur
- University Hospital of Internal Medicine V, Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria
| | - Johannes Clausen
- Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria
| |
Collapse
|
14
|
Loufouma Mbouaka A, Gamble M, Wurst C, Jäger HY, Maixner F, Zink A, Noedl H, Binder M. The elusive parasite: comparing macroscopic, immunological, and genomic approaches to identifying malaria in human skeletal remains from Sayala, Egypt (third to sixth centuries AD). Archaeol Anthropol Sci 2021; 13:115. [PMID: 34149953 PMCID: PMC8202054 DOI: 10.1007/s12520-021-01350-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Accepted: 04/19/2021] [Indexed: 05/12/2023]
Abstract
UNLABELLED Although malaria is one of the oldest and most widely distributed diseases affecting humans, identifying and characterizing its presence in ancient human remains continue to challenge researchers. We attempted to establish a reliable approach to detecting malaria in human skeletons using multiple avenues of analysis: macroscopic observations, rapid diagnostic tests, and shotgun-capture sequencing techniques, to identify pathological changes, Plasmodium antigens, and Plasmodium DNA, respectively. Bone and tooth samples from ten individuals who displayed skeletal lesions associated with anaemia, from a site in southern Egypt (third to sixth centuries AD), were selected. Plasmodium antigens were detected in five of the ten bone samples, and traces of Plasmodium aDNA were detected in six of the twenty bone and tooth samples. There was relatively good synchronicity between the biomolecular findings, despite not being able to authenticate the results. This study highlights the complexity and limitations in the conclusive identification of the Plasmodium parasite in ancient human skeletons. Limitations regarding antigen and aDNA preservation and the importance of sample selection are at the forefront of the search for malaria in the past. We confirm that, currently, palaeopathological changes such as cribra orbitalia are not enough to be certain of the presence of malaria. While biomolecular methods are likely the best chance for conclusive identification, we were unable to obtain results which correspond to the current authentication criteria of biomolecules. This study represents an important contribution in the refinement of biomolecular techniques used; also, it raises new insight regarding the consistency of combining several approaches in the identification of malaria in past populations. SUPPLEMENTARY INFORMATION The online version contains supplementary material available at 10.1007/s12520-021-01350-z.
Collapse
Affiliation(s)
- Alvie Loufouma Mbouaka
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria
| | - Michelle Gamble
- Bioarchaeology Department, Austrian Archaeological Institute at the Austrian Academy of Sciences, Franz Klein-Gasse 1, 1190 Vienna, Austria
- Present Address: Heritage and Archaeological Research Practice, 101 Rose Street South Lane, EH2 3JG Edinburgh, Scotland
| | - Christina Wurst
- Institute for Mummy Studies, EURAC Research, Viale Druso 1, 39100 Bolzano, Italy
| | - Heidi Yoko Jäger
- Institute for Mummy Studies, EURAC Research, Viale Druso 1, 39100 Bolzano, Italy
| | - Frank Maixner
- Institute for Mummy Studies, EURAC Research, Viale Druso 1, 39100 Bolzano, Italy
| | - Albert Zink
- Institute for Mummy Studies, EURAC Research, Viale Druso 1, 39100 Bolzano, Italy
| | - Harald Noedl
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria
- Present Address: Malaria Research Initiative Bandarban, Vienna, Austria
| | - Michaela Binder
- Bioarchaeology Department, Austrian Archaeological Institute at the Austrian Academy of Sciences, Franz Klein-Gasse 1, 1190 Vienna, Austria
- Present Address: Planen und Bauen im Bestand, Novetus, Belvederegasse 41, 1040 Vienna, Austria
| |
Collapse
|
15
|
Haridas S, Albert R, Binder M, Bloem J, LaButti K, Salamov A, Andreopoulos B, Baker SE, Barry K, Bills G, Bluhm BH, Cannon C, Castanera R, Culley DE, Daum C, Ezra D, González JB, Henrissat B, Kuo A, Liang C, Lipzen A, Lutzoni F, Magnuson J, Mondo SJ, Nolan M, Ohm RA, Pangilinan J, Park HJ, Ramírez L, Alfaro M, Sun H, Tritt A, Yoshinaga Y, Zwiers LH, Turgeon BG, Goodwin SB, Spatafora JW, Crous PW, Grigoriev IV. 101 Dothideomycetes genomes: A test case for predicting lifestyles and emergence of pathogens. Stud Mycol 2020; 96:141-153. [PMID: 32206138 PMCID: PMC7082219 DOI: 10.1016/j.simyco.2020.01.003] [Citation(s) in RCA: 92] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Dothideomycetes is the largest class of kingdom Fungi and comprises an incredible diversity of lifestyles, many of which have evolved multiple times. Plant pathogens represent a major ecological niche of the class Dothideomycetes and they are known to infect most major food crops and feedstocks for biomass and biofuel production. Studying the ecology and evolution of Dothideomycetes has significant implications for our fundamental understanding of fungal evolution, their adaptation to stress and host specificity, and practical implications with regard to the effects of climate change and on the food, feed, and livestock elements of the agro-economy. In this study, we present the first large-scale, whole-genome comparison of 101 Dothideomycetes introducing 55 newly sequenced species. The availability of whole-genome data produced a high-confidence phylogeny leading to reclassification of 25 organisms, provided a clearer picture of the relationships among the various families, and indicated that pathogenicity evolved multiple times within this class. We also identified gene family expansions and contractions across the Dothideomycetes phylogeny linked to ecological niches providing insights into genome evolution and adaptation across this group. Using machine-learning methods we classified fungi into lifestyle classes with >95 % accuracy and identified a small number of gene families that positively correlated with these distinctions. This can become a valuable tool for genome-based prediction of species lifestyle, especially for rarely seen and poorly studied species.
Collapse
Key Words
- Aulographales Crous, Spatafora, Haridas & Grigoriev
- Coniosporiaceae Crous, Spatafora, Haridas & Grigoriev
- Coniosporiales Crous, Spatafora, Haridas & Grigoriev
- Eremomycetales Crous, Spatafora, Haridas & Grigoriev
- Fungal evolution
- Genome-based prediction
- Lineolataceae Crous, Spatafora, Haridas & Grigoriev
- Lineolatales Crous, Spatafora, Haridas & Grigoriev
- Machine-learning
- New taxa
- Rhizodiscinaceae Crous, Spatafora, Haridas & Grigoriev
Collapse
Affiliation(s)
- S Haridas
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - R Albert
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.,Department of Plant and Microbial Biology, University of California Berkeley, Berkeley, CA, USA
| | - M Binder
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands
| | - J Bloem
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands
| | - K LaButti
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - A Salamov
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - B Andreopoulos
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - S E Baker
- Functional and Systems Biology Group, Environmental Molecular Sciences Division, Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, Washington, USA
| | - K Barry
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - G Bills
- University of Texas Health Science Center, Houston, TX, USA
| | - B H Bluhm
- University of Arkansas, Fayelletville, AR, USA
| | - C Cannon
- Texas Tech University, Lubbock, TX, USA
| | - R Castanera
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.,Institute for Multidisciplinary Research in Applied Biology (IMAB-UPNA), Universidad Pública de Navarra, Pamplona, Navarra, Spain
| | - D E Culley
- Functional and Systems Biology Group, Environmental Molecular Sciences Division, Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, Washington, USA
| | - C Daum
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - D Ezra
- Agricultural Research Organization, Volcani Center, Rishon LeTsiyon, Israel
| | - J B González
- Section of Plant Pathology and Plant-Microbe Biology, School of Integrative Plant Science, Cornell University, Ithaca, NY, USA
| | - B Henrissat
- CNRS, Aix-Marseille Université, Marseille, France.,INRA, Marseille, France.,Department of Biological Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| | - A Kuo
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - C Liang
- College of Agronomy and Plant Protection, Qingdao Agricultural University, China
| | - A Lipzen
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - F Lutzoni
- Department of Biology, Duke University, Durham, NC, USA
| | - J Magnuson
- Functional and Systems Biology Group, Environmental Molecular Sciences Division, Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, Washington, USA
| | - S J Mondo
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.,Bioagricultural Science and Pest Management Department, Colorado State University, Fort Collins, CO, USA
| | - M Nolan
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - R A Ohm
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.,Microbiology, Department of Biology, Faculty of Science, Utrecht University, Utrecht, The Netherlands
| | - J Pangilinan
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - H-J Park
- Section of Plant Pathology and Plant-Microbe Biology, School of Integrative Plant Science, Cornell University, Ithaca, NY, USA
| | - L Ramírez
- Institute for Multidisciplinary Research in Applied Biology (IMAB-UPNA), Universidad Pública de Navarra, Pamplona, Navarra, Spain
| | - M Alfaro
- Institute for Multidisciplinary Research in Applied Biology (IMAB-UPNA), Universidad Pública de Navarra, Pamplona, Navarra, Spain
| | - H Sun
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - A Tritt
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - Y Yoshinaga
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - L-H Zwiers
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands
| | - B G Turgeon
- Section of Plant Pathology and Plant-Microbe Biology, School of Integrative Plant Science, Cornell University, Ithaca, NY, USA
| | - S B Goodwin
- U.S. Department of Agriculture-Agricultural Research Service, 915 W. State Street, West Lafayette, IN, USA
| | - J W Spatafora
- Department of Botany & Plant Pathology, Oregon State University, Oregon State University, Corvallis, OR, USA
| | - P W Crous
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Microbiology, Department of Biology, Faculty of Science, Utrecht University, Utrecht, The Netherlands
| | - I V Grigoriev
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.,Department of Plant and Microbial Biology, University of California Berkeley, Berkeley, CA, USA
| |
Collapse
|
16
|
Witte S, Medenwald D, Golla A, Shehu E, Vordermark D, Michl P, Binder M, Ruessel J, Steckelberg A, Schmidt H. TRAINING PROGRAMS PROMOTING DAILY ACTIVITY AND PHYSICAL FUNCTION OF OLDER PATIENTS WITH CANCER: A QUESTIONNAIRE-BASED SURVEY REGARDING INDIVIDUAL NEEDS AND PREFERENCES. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31240-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Goekkurt E, Binder M, Lorenzen S, Thuss-Patience P, Al-Batran SE, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A. Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Binder M, Quade L. Death on a Napoleonic battlefield - Peri-mortem trauma in soldiers from the Battle of Aspern 1809. Int J Paleopathol 2018; 22:66-77. [PMID: 29886352 DOI: 10.1016/j.ijpp.2018.05.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Revised: 05/28/2018] [Accepted: 05/30/2018] [Indexed: 06/08/2023]
Abstract
On the 21st-22nd of May1809 Napoleon Bonaparte saw his first major defeat on land at the Battle of Aspern, just north-east of Vienna. Of the 167,000 soldiers who fought for the French and Austrian armies, a total of 55,000 died on the battlefield. Salvage excavations prior to the construction of large urban development project (2008-2016) have revealed several burial sites related to the Battle of Aspern. The skeletal remains of 30 soldiers were excavated and underwent a detailed bioarchaeological study to elucidate both the impact of 19th-century military conditions on soldiers in life, as well as how they died on the battlefield. This paper presents the analysis of peri-mortem trauma observed in 21 of the 30 skeletons (70.0%) excavated from the battlefield of Aspern. Following standard criteria in forensic and palaeopathological trauma studies, this study revealed a predominance of ballistic trauma (20 cases in 17 individuals), while only nine individuals (eleven cases) displayed evidence of blunt force trauma. By contrast, no evidence of sharp force trauma was identified in the skeletal remains. These results are discussed within the historic context of the Napoleonic Wars to reconstruct causes of injury and circumstances of death.
Collapse
Affiliation(s)
- Michaela Binder
- Austrian Archaeological Institute, Austrian Academy of Sciences, Franz Klein-Gasse 1, 1190, Vienna, Austria.
| | - Leslie Quade
- Department of Archaeology, Durham University, South Road, DH13LE, Durham, UK
| |
Collapse
|
19
|
Quade L, Binder M. Life on a Napoleonic battlefield: A bioarchaeological analysis of soldiers from the Battle of Aspern, Austria. Int J Paleopathol 2018; 22:23-38. [PMID: 29627582 DOI: 10.1016/j.ijpp.2018.03.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2017] [Revised: 03/14/2018] [Accepted: 03/21/2018] [Indexed: 06/08/2023]
Abstract
On the 21st-22nd of May 1809, French and Austrian soldiers engaged in battle near the village of Aspern on the outskirts of Vienna. This battle, the first defeat of Napoleon's army on land, was one of the largest and deadliest encounters during the Napoleonic Wars (1798-1815). Salvage excavations between 2009 and 2016 have revealed several battlefield burial sites in Aspern. The remains of 30 individuals were evaluated for a series of pathological conditions which develop during childhood and adulthood to elucidate the impact of Napoleonic military conditions on health. Statistical comparisons were conducted of stature estimates and frequencies of pathological conditions between the Aspern soldiers, several contemporaneous military, and two civilian samples of differing socioeconomic status. These data were compared to test the hypothesis that military conscripts had 'healthy' childhoods, but then experienced deteriorating health as a result of military conditions. The analysis revealed comparatively high mean stature, but also a high prevalence of enamel hypoplastic defects, indicating that the childhood health of the military recruits was more varied than was initially expected. High frequencies of carious lesions, dental calculus, active maxillary sinusitis and pleuritis and osteoarthritis were recorded, demonstrating the deleterious effects of military life on health.
Collapse
Affiliation(s)
- Leslie Quade
- Austrian Archaeological Institute/Austrian Academy of Sciences, Franz Klein-Gasse 1, A-1190 Vienna, Austria; Durham University, Department of Archaeology, South Road, Durham DH1 3LE, United Kingdom.
| | - Michaela Binder
- Austrian Archaeological Institute/Austrian Academy of Sciences, Franz Klein-Gasse 1, A-1190 Vienna, Austria
| |
Collapse
|
20
|
Abstract
ZusammenfassungDie oberflächliche Thrombophlebitis ist eine häufige Erkrankung, von der Frauen aufgrund ihrer Risikofaktoren stärker betroffen sind als Männer. Diagnostisch sollte eine eventuell gleichzeitig vorkommende tiefe Venenthrombose mit bildgebenden Verfahren abgegrenzt werden. In der Therapie sind Heparin bzw. niedermolekulare Heparine indiziert, wenn tiefe Venenthrombosen vorliegen bzw. ein Risiko hierfür besteht. Im akuten Stadium können nichtsteroidale Antiphlogistika oral genommen werden, um Schmerz und Entzündung zu lindern. Liegt gleichzeitig eine chronisch venöse Insuffizienz vor, unterstützen so genannte Ödemprotektiva (z.B. Rosskastaniensamenextrakt und flavonoidhaltige Präparate) die Behandlung.Bei entzündlichen Veränderungen relativ kurzer oberflächlicher Venenabschnitte ohne Beteiligung des tiefen Venensystems ist die Beschränkung auf lokale Behandlungsmaßnahmen möglich. Neben der Kompressionstherapie sind mehrmalige tägliche Anwendungen heparin- und heparinoidhaltiger Salben bzw. Gele üblich.Bewährt hat sich insbesondere die Anwendung von topischen Präparaten, die Mukopolysaccharidpolyschwefelsäureester (MPS) enthalten.Die Problematik, die Wirksamkeit topischer Präparate bei der Behandlung der oberflächlichen Thrombophlebitis unter den gegenwärtig strengen Kautelen unserer Aufsichtsbehörde nachzuweisen und neue Produkte zu entwickeln, wird diskutiert.
Collapse
|
21
|
Bera TK, Abe Y, Ise T, Oberle A, Gallardo D, Liu XF, Nagata S, Binder M, Pastan I. Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients. Leukemia 2017; 32:569-572. [PMID: 29149102 PMCID: PMC5808081 DOI: 10.1038/leu.2017.315] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- T K Bera
- Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer Biology Research, Bethesda, MD, USA
| | - Y Abe
- Center, Sanford Research, Sioux Falls, SD, USA
| | - T Ise
- Center, Sanford Research, Sioux Falls, SD, USA
| | - A Oberle
- Klinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany
| | - D Gallardo
- Leidos Biomedical Research, Inc., National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - X-F Liu
- Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer Biology Research, Bethesda, MD, USA
| | - S Nagata
- Center, Sanford Research, Sioux Falls, SD, USA
| | - M Binder
- Klinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany
| | - I Pastan
- Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer Biology Research, Bethesda, MD, USA
| |
Collapse
|
22
|
Binder M, Saad M. Hypertrophic osteoarthropathy in a young adult male from Berber, Sudan (2nd-3rd century CE). Int J Paleopathol 2017; 18:52-62. [PMID: 28888393 DOI: 10.1016/j.ijpp.2017.05.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Revised: 05/02/2017] [Accepted: 05/15/2017] [Indexed: 06/07/2023]
Abstract
Hypertrophic osteoarthropathy (HOA) is a pathological condition characterised by extensive periosteal new bone formation (NBF) on the diaphyses of the long bones, metacarpal and metatarsal bones. In modern clinical contexts, the secondary form of the disease is common and most often occurs secondary to intra-thoracic cancer and other forms of chronic pulmonary disease. Paleopathological evidence for HOA on the other hand has only occasionally been reported. Here we report a young adult male from the Meriotic cemetery at Berber in Sudan (2nd-3rd century CE) displaying widespread NBF on the diaphyses of the upper and lower limb bones, metacarpal and metatarsal bones, as well as the pelvis and scapulae. While several pathological conditions have to be considered as differential diagnostic options for NBF in the post-cranial skeleton, HOA is the most likely diagnosis, based on the distribution of the changes observed in this individual, as well as their macroscopic and radiographic characteristics. A chronic pulmonary condition as indicated by NBF on the visceral side of the ribs may represent the underlying cause for the HOA. This individual represents the first paleopathological case of HOA reported from an archaeological site in Africa.
Collapse
Affiliation(s)
- M Binder
- Austrian Archaeological Institute, Austrian Academy of Sciences, Franz Klein-Gasse 1, 1190 Vienna, Austria.
| | - M Saad
- National Corporation for Antiquities and Museums of Sudan, PO Box 178, Khartoum, Sudan
| |
Collapse
|
23
|
Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia 2017; 31:2623-2629. [PMID: 28559537 DOI: 10.1038/leu.2017.170] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 05/08/2017] [Accepted: 05/15/2017] [Indexed: 01/08/2023]
Abstract
To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL), we conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL failing high-dose methotrexate)-based chemotherapy. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for HCT-ASCT consisted of rituximab 375 mg/m2, carmustine 400 mg/m2 and thiotepa (4 × 5 mg/kg). Patients commenced HCT-ASCT irrespective of response after induction. Patients not achieving complete remission (CR) after HCT-ASCT received whole-brain radiotherapy. Primary end point was CR after HCT-ASCT. We enrolled 39 patients; median age and Karnofsky performance score are 57 years and 90%, respectively. About 28 patients had relapsed and 8 refractory disease. About 22 patients responded to induction and 32 patients commenced HCT-ASCT. About 22 patients (56.4%) achieved CR after HCT-ASCT. Respective 2-year progression-free survival (PFS) and overall survival (OS) rates were 46.0% (median PFS 12.4 months) and 56.4%; median OS not reached. We recorded four treatment-related deaths. Thiotepa-based HCT-ASCT is an effective treatment option in eligible patients with r/r PCNSL. Comparative studies are needed to further scrutinise the role of HCT-ASCT in the salvage setting.
Collapse
Affiliation(s)
- B Kasenda
- Department of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany.,Department of Medical Oncology & Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - G Ihorst
- Clinical Trials Unit, Medical Centre - University of Freiburg, Freiburg, Germany
| | - R Schroers
- Department of Medicine, Hematology and Oncology, Ruhr-University of Bochum, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany
| | - A Korfel
- Department of Hematology, Oncology and Tumor Immunology, Charite University Medicine, Berlin, Germany
| | - I Schmidt-Wolf
- Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany
| | - G Egerer
- Department of Haematology and Oncology, Heidelberg University, Heidelberg, Germany
| | - L von Baumgarten
- Department of Neurology, University Hospital Munich LMU, Munich, Germany
| | - A Röth
- Medical Faculty, Department of Haematology, University of Duisburg-Essen, Essen, Germany
| | - J Bloehdorn
- Department of Internal Medicine III, University of Ulm, Ulm, Germany
| | - R Möhle
- Department of Haematology and Oncology, University Tübingen, Tübingen, Germany
| | - M Binder
- Department of Oncology and Hematology, University of Hamburg, Hamburg, Germany
| | - U Keller
- III Medical Department, Technische Universität München, Munich, Germany
| | - M Lamprecht
- Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Campus Kiel, Germany
| | - M Pfreundschuh
- Klinik für Innere Medizin I, Universität des Saarlandes, Homburg, Germany
| | - E Valk
- Department of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany
| | - H Fricker
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - E Schorb
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - K Fritsch
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - J Finke
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - G Illerhaus
- Department of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany.,Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| |
Collapse
|
24
|
Bobrowski P, Jórdeczka M, Sobkowiak-Tabaka I, Binder M. Khor Shambat, Early Khartoum, Neolithic, cemetery, graves, settlement, pottery, lithic inventory, archaeozoology. ACTA ACUST UNITED AC 2017. [DOI: 10.5604/01.3001.0010.1870] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The locality of Khor Shambat in the Omdurman district of Khartoum was investigated in 2012. The site lies between two gorges draining water to the Nile Valley from the west. Testing established the site stratigraphy, dating the cultural level to the early Neolithic. The source material from this cultural level included vessel-type ceramics, microlithic stone artifacts, macrolithic stone tools and faunal remains. A cemetery containing 13 graves was investigated, the alignment of the burial pits and position of the interments leading to the conclusion that it started as a Neolithic burial ground and continued as a cemetery probably in Meroitic and post-Meroitic times. The archaeological, anthropological and archaeozoological data contributed new information on settlement on this site and in the broader overview, in central Sudan.
Collapse
Affiliation(s)
- Przemysław Bobrowski
- Institute of Archaeology and Ethnology, Polish Academy of Sciences Poznań Branch Centre for Prehistoric and Medieval Studies, African Prehistoric and Early Civilisation Research Group
| | | | | | | |
Collapse
|
25
|
Podboy A, Sunjaya D, Smyrk TC, Murray JA, Binder M, Katzka DA, Alexander JA, Halland M. Oesophageal lichen planus: the efficacy of topical steroid-based therapies. Aliment Pharmacol Ther 2017; 45:310-318. [PMID: 27859412 DOI: 10.1111/apt.13856] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Revised: 08/26/2016] [Accepted: 10/15/2016] [Indexed: 12/18/2022]
Abstract
BACKGROUND Oesophageal lichen planus is an idiopathic inflammatory disorder characterized by significant oesophageal stricturing. Oesophageal lichen planus is a rare, difficult to diagnose, and likely an under recognized disease. As a result, there is no standardized approach to therapy and treatment strategies vary. AIM To examine the utility of topical steroid therapy (fluticasone or budesonide) in the management of oesophageal lichen planus. METHODS A retrospective chart review was conducted of patients diagnosed with oesophageal lichen planus who underwent baseline and follow up endoscopy pre and post topical steroid therapy between 1995 and 2016 at Mayo Clinic, Rochester MN. Average time between upper GI endoscopy was 3.2 months (0.7-11.7). Swallowed steroid preparations included fluticasone 880 μg twice daily or budesonide 3 mg twice daily. Patients were reviewed for symptomatic response to therapy using the Dakkak-Bennett dysphagia score (0-4, no dysphagia to total aphagia). Pre- and post-endoscopic findings were assessed. Additional baseline demographic, endoscopic, and histologic data were also obtained. RESULTS We identified 40 patients who met the inclusion criteria. A significant reduction in median dysphagia score from 1 (0-4) to 0 (0-3) after steroid therapy (P < 0.001) was noted. 62% of patients reported resolution of their dysphagia after receiving topical corticosteroids. 72.5% had an endoscopic response to steroid therapy. CONCLUSION Topical swallowed budesonide or fluticasone appear to effective treatment for oesophageal lichen planus.
Collapse
Affiliation(s)
- A Podboy
- Division of Internal Medicine and Graduate Medical Education, Mayo Clinic, Rochester, MN, USA
| | - D Sunjaya
- Division of Internal Medicine and Graduate Medical Education, Mayo Clinic, Rochester, MN, USA
| | - T C Smyrk
- Division of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - J A Murray
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
| | - M Binder
- Division of Internal Medicine and Graduate Medical Education, Mayo Clinic, Rochester, MN, USA
| | - D A Katzka
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
| | - J A Alexander
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
| | - M Halland
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
26
|
Abstract
The aim of this study was to identify the functional anatomy of the cerebral speech regions involved in speaking in native and foreign language in the same subject using functional magnetic resonance imaging. Experimental design consisted of two activation runs. Each of them included two kinds of tasks arranged in series of five blocks lasting for 30s. In the experimental condition of the first run subjects were required to speak in their native language and in the second run the task was to speak in the foreign language. In both runs, baseline condition was the same and subjects were supposed to lie silently inside the bore. We observed the influence of proficiency on brain activation. In subjects with equal proficiency in the first and the second language, differences were not observed. In the subjects with unequal proficiency in the first and the second language we observed two main effects. First was difference in the strength and extension of activation, the second effect was activation of new regions for the second language, in which proficiency was lower.
Collapse
Affiliation(s)
| | - M. Binder
- Department of Psychophysiology; Jagiellonian Universtity, Cracow, Poland
| | | | | |
Collapse
|
27
|
Binder M. Weiss, Elizabeth. Paleopathology in perspective: bone health and disease through time. xiv, 249 pp., illus., figs, bibliogr. Lanham, Md: Rowman & Littlefield, 2015. £37.95 (paper). J R Anthropol Inst 2016. [DOI: 10.1111/1467-9655.12515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Kebreab E, Liedke A, Caro D, Deimling S, Binder M, Finkbeiner M. Environmental impact of using specialty feed ingredients in swine and poultry production: A life cycle assessment. J Anim Sci 2016; 94:2664-81. [PMID: 27285941 DOI: 10.2527/jas.2015-9036] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Livestock production has a variety of environmental impacts such as greenhouse gas emissions, water pollution, acidification, and primary energy consumption. The demand for livestock products is expected to grow substantially, creating even more environmental pressure. The use of specialty feed ingredients (SFI) such as supplemented AA and phytase can reduce nutrient input into the system without compromising productivity and consequently can reduce emissions. The global change impact of using SFI in pig and broiler production systems in Europe and North and South America was studied. A life cycle assessment according to international standards (ISO 14040/44) analyzed contributions from producing SFI and animals to global change. Three different alternatives were analyzed. In addition, partial sensitivity analysis was conducted using 5 scenarios for each region for both production systems. Specialty feed ingredient supplementation in pig and broiler diets reduced greenhouse gas emissions (cradle to farm gate) by 56% and 54% in Europe, 17% and 15% in North America, and 33% and 19% in South America, respectively, compared to an unsupplemented diet. A total of 136 Mt CO equivalent (CO eq) was saved in 2012, rising to 146 Mt CO eq in 2050 on the basis of United Nations population projections. Considerable benefits of supplementation with SFI were apparent in European and South American diets when direct land use change was considered because of the reduced demand for soybean meal. The eutrophication potential of unsupplemented diets was reduced by up to 35% in pig and 49% in broiler production systems compared to supplemented alternatives. The acidification potential of supplemented strategies was reduced by up to 30% in pig and 79% in broiler production systems. The primary energy demand was similar in all alternatives, and this could be an area where the SFI industry can improve. Overall, SFI supplementation substantially reduced the global warming, eutrophication, and acidification potentials in all regions studied.
Collapse
|
29
|
Binder M. Neural correlates of audiovisual temporal processing – Comparison of temporal order and simultaneity judgments. Neuroscience 2015; 300:432-47. [DOI: 10.1016/j.neuroscience.2015.05.011] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Revised: 05/05/2015] [Accepted: 05/06/2015] [Indexed: 01/09/2023]
|
30
|
McKinnon R, Binder M, Zupkó I, Afonyushkin T, Lajter I, Vasas A, de Martin R, Unger C, Dolznig H, Diaz R, Frisch R, Passreiter CM, Krupitza G, Hohmann J, Kopp B, Bochkov VN. Pharmacological insight into the anti-inflammatory activity of sesquiterpene lactones from Neurolaena lobata (L.) R.Br. ex Cass. Phytomedicine 2014; 21:1695-1701. [PMID: 25442279 DOI: 10.1016/j.phymed.2014.07.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Revised: 07/23/2014] [Accepted: 07/29/2014] [Indexed: 06/04/2023]
Abstract
PURPOSE Neurolaena lobata is a Caribbean medicinal plant used for the treatment of several conditions including inflammation. Recent data regarding potent anti-inflammatory activity of the plant and isolated sesquiterpene lactones raised our interest in further pharmacological studies. The present work aimed at providing a mechanistic insight into the anti-inflammatory activity of N. lobata and eight isolated sesquiterpene lactones, as well as a structure-activity relationship and in vivo anti-inflammatory data. METHODS The effect of the extract and its compounds on the generation of pro-inflammatory proteins was assessed in vitro in endothelial and monocytic cells by enzyme-linked immunosorbent assay. Their potential to modulate the expression of inflammatory genes was further studied at the mRNA level. In vivo anti-inflammatory activity of the chemically characterized extract was evaluated using carrageenan-induced paw edema model in rats. RESULTS The compounds and extract inhibited LPS- and TNF-α-induced upregulation of the pro-inflammatory molecules E-selectin and interleukin-8 in HUVECtert and THP-1 cells. LPS-induced elevation of mRNA encoding for E-selectin and interleukin-8 was also suppressed. Furthermore, the extract inhibited the development of acute inflammation in rats. CONCLUSIONS Sesquiterpene lactones from N. lobata interfered with the induction of inflammatory cell adhesion molecules and chemokines in cells stimulated with bacterial products and cytokines. Structure-activity analysis revealed the importance of the double bond at C-4-C-5 and C-2-C-3 and the acetyl group at C-9 for the anti-inflammatory activity. The effect was confirmed in vivo, which raises further interest in the therapeutic potential of the compounds for the treatment of inflammatory diseases.
Collapse
Affiliation(s)
- R McKinnon
- Department of Pharmacognosy, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria.
| | - M Binder
- Department of Vascular Biology and Thrombosis Research, Center of Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| | - I Zupkó
- Department of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
| | - T Afonyushkin
- Department of Vascular Biology and Thrombosis Research, Center of Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| | - I Lajter
- Department of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
| | - A Vasas
- Department of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
| | - R de Martin
- Department of Vascular Biology and Thrombosis Research, Center of Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| | - C Unger
- Institute of Medical Genetics, Medical University of Vienna, Währinger Strasse 10, A-1090 Vienna, Austria
| | - H Dolznig
- Institute of Medical Genetics, Medical University of Vienna, Währinger Strasse 10, A-1090 Vienna, Austria
| | - R Diaz
- Institute of Ethnobiology, Playa Diana, San José/Petén, Guatemala
| | - R Frisch
- Institute of Ethnobiology, Playa Diana, San José/Petén, Guatemala
| | - C M Passreiter
- Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine-University Düsseldorf, Universitätsstrasse 1, D-40225 Düsseldorf, Germany
| | - G Krupitza
- Clinical Institute of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria
| | - J Hohmann
- Department of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
| | - B Kopp
- Department of Pharmacognosy, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria
| | - V N Bochkov
- Department of Vascular Biology and Thrombosis Research, Center of Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| |
Collapse
|
31
|
Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. Leukemia 2014; 29:696-704. [PMID: 25102945 DOI: 10.1038/leu.2014.236] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2014] [Revised: 07/11/2014] [Accepted: 07/28/2014] [Indexed: 11/09/2022]
Abstract
Multiple myeloma is a mostly incurable malignancy characterized by the expansion of a malignant plasma cell (PC) clone in the human bone marrow (BM). Myeloma cells closely interact with the BM stroma, which secretes soluble factors that foster myeloma progression and therapy resistance. Growth arrest-specific gene 6 (Gas6) is produced by BM-derived stroma cells and can promote malignancy. However, the role of Gas6 and its receptors Axl, Tyro3 and Mer (TAM receptors) in myeloma is unknown. We therefore investigated their expression in myeloma cell lines and in the BM of myeloma patients and healthy donors. Gas6 showed increased expression in sorted BMPCs of myeloma patients compared with healthy controls. The fraction of Mer(+) BMPCs was increased in myeloma patients in comparison with healthy controls whereas Axl and Tyro3 were not expressed by BMPCs in the majority of patients. Downregulation of Gas6 and Mer inhibited the proliferation of different myeloma cell lines, whereas knocking down Axl or Tyro3 had no effect. Inhibition of the Gas6 receptor Mer or therapeutic targeting of Gas6 by warfarin reduced myeloma burden and improved survival in a systemic model of myeloma. Thus, the Gas6-Mer axis represents a novel candidate for therapeutic intervention in this incurable malignancy.
Collapse
Affiliation(s)
- J S Waizenegger
- 1] Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany [2] Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - I Ben-Batalla
- 1] Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany [2] Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - N Weinhold
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - T Meissner
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
| | - M Wroblewski
- 1] Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany [2] Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Janning
- 1] Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany [2] Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Riecken
- Department of Stem Cell Transplantation, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Binder
- Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Atanackovic
- Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - H Taipaleenmaeki
- Heisenberg-Group for Molecular Skeletal Biology, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Schewe
- Department of Pediatrics, University Medical Center Schleswig-Holstein, Kiel, Germany
| | - S Sawall
- 1] Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany [2] Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - V Gensch
- 1] Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany [2] Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Cubas-Cordova
- 1] Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany [2] Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Seckinger
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - W Fiedler
- Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - E Hesse
- Heisenberg-Group for Molecular Skeletal Biology, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - N Kröger
- Department of Stem Cell Transplantation, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - B Fehse
- Department of Stem Cell Transplantation, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Hose
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - B Klein
- Institute of Research in Biotherapy, University Hospital of Montpellier (CHU), Montpellier, France
| | - M S Raab
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - K Pantel
- Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - C Bokemeyer
- Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Loges
- 1] Department of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany [2] Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
32
|
Engeli L, Moergeli H, Binder M, Drabe N, Meier C, Buechi S, Dummer R, Jenewein J. Resilience in patients and spouses faced with malignant melanoma. A qualitative longitudinal study. Eur J Cancer Care (Engl) 2014; 25:122-31. [PMID: 25070508 DOI: 10.1111/ecc.12220] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2014] [Indexed: 11/28/2022]
Abstract
Life-threatening diseases like malignant tumours are associated with considerable existential distress. Little is known about the factors that promote resilience within these individuals. This longitudinal qualitative partner study aimed to analyse resilience as per Antonovsky's sense of coherence. Eight patients with malignant melanoma and their partners were interviewed. They were asked about their coping strategies, attitudes towards the meaning of life and their cancer, and comprehension of what is happening to them. The questions were asked shortly after their diagnosis was made and 6 months later. All interviews were audio-taped and later transcribed and analysed according to the method of qualitative content analysis described by P. Mayring. At baseline, the majority of statements made (261; patients = 141/spouses = 120) related to coping/manageability of disease, with only 26 statements (patients = 15/spouses = 11) related to meaning and 127 (patients = 64/spouses = 63) to comprehension. There were no significant differences between the responses of patients and their partners and no significant changes in the number of statements during the 6-month interview. The most significant theme that emerged was manageability of disease, with distraction the most commonly utilised coping skill. The comprehension and meaning themes were far less prevalent. Hence, support should focus on disease and situational manageability.
Collapse
Affiliation(s)
- L Engeli
- Psychiatric Hospital of the University of Basel, Basel, Switzerland
| | - H Moergeli
- Department of Psychiatry and Psychotherapy, University Hospital Zurich, Zurich, Switzerland
| | - M Binder
- Department of Psychiatry and Psychotherapy, University Hospital Zurich, Zurich, Switzerland
| | - N Drabe
- Department of Psychiatry and Psychotherapy, University Hospital Zurich, Zurich, Switzerland
| | - C Meier
- Department of Psychiatry and Psychotherapy, University Hospital Zurich, Zurich, Switzerland
| | - S Buechi
- Private Clinic for Psychotherapy and Psychosomatics 'Hohenegg', Meilen, Switzerland
| | - R Dummer
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | - J Jenewein
- Department of Psychiatry and Psychotherapy, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
33
|
Binder M, Roberts C, Spencer N, Antoine D, Cartwright C. On the antiquity of cancer: evidence for metastatic carcinoma in a young man from ancient Nubia (c. 1200 BC). PLoS One 2014; 9:e90924. [PMID: 24637948 PMCID: PMC3956457 DOI: 10.1371/journal.pone.0090924] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2013] [Accepted: 02/06/2014] [Indexed: 01/09/2023] Open
Abstract
Cancer, one of the world’s leading causes of death today, remains almost absent relative to other pathological conditions, in the archaeological record, giving rise to the conclusion that the disease is mainly a product of modern living and increased longevity. This paper presents a male, young-adult individual from the archaeological site of Amara West in northern Sudan (c. 1200BC) displaying multiple, mainly osteolytic, lesions on the vertebrae, ribs, sternum, clavicles, scapulae, pelvis, and humeral and femoral heads. Following radiographic, microscopic and scanning electron microscopic (SEM) imaging of the lesions, and a consideration of differential diagnoses, a diagnosis of metastatic carcinoma secondary to an unknown soft tissue cancer is suggested. This represents the earliest complete example in the world of a human who suffered metastatic cancer to date. The study further draws its strength from modern analytical techniques applied to differential diagnoses and the fact that it is firmly rooted within a well-documented archaeological and historical context, thus providing new insights into the history and antiquity of the disease as well as its underlying causes and progression.
Collapse
Affiliation(s)
- Michaela Binder
- Department of Archaeology, Durham University, Durham, United Kingdom
- * E-mail:
| | - Charlotte Roberts
- Department of Archaeology, Durham University, Durham, United Kingdom
| | - Neal Spencer
- Department of Ancient Egypt and Sudan, British Museum, London, United Kingdom
| | - Daniel Antoine
- Department of Ancient Egypt and Sudan, British Museum, London, United Kingdom
| | - Caroline Cartwright
- Department of Conservation and Scientific Research, British Museum, London, United Kingdom
| |
Collapse
|
34
|
Abstract
Alternaria is a ubiquitous fungal genus that includes saprobic, endophytic and pathogenic species associated with a wide variety of substrates. In recent years, DNA-based studies revealed multiple non-monophyletic genera within the Alternaria complex, and Alternaria species clades that do not always correlate to species-groups based on morphological characteristics. The Alternaria complex currently comprises nine genera and eight Alternaria sections. The aim of this study was to delineate phylogenetic lineages within Alternaria and allied genera based on nucleotide sequence data of parts of the 18S nrDNA, 28S nrDNA, ITS, GAPDH, RPB2 and TEF1-alpha gene regions. Our data reveal a Pleospora/Stemphylium clade sister to Embellisia annulata, and a well-supported Alternaria clade. The Alternaria clade contains 24 internal clades and six monotypic lineages, the assemblage of which we recognise as Alternaria. This puts the genera Allewia, Brachycladium, Chalastospora, Chmelia, Crivellia, Embellisia, Lewia, Nimbya, Sinomyces, Teretispora, Ulocladium, Undifilum and Ybotromyces in synonymy with Alternaria. In this study, we treat the 24 internal clades in the Alternaria complex as sections, which is a continuation of a recent proposal for the taxonomic treatment of lineages in Alternaria. Embellisia annulata is synonymised with Dendryphiella salina, and together with Dendryphiella arenariae, are placed in the new genus Paradendryphiella. The sexual genera Clathrospora and Comoclathris, which were previously associated with Alternaria, cluster within the Pleosporaceae, outside Alternaria s. str., whereas Alternariaster, a genus formerly seen as part of Alternaria, clusters within the Leptosphaeriaceae. Paradendryphiella is newly described, the generic circumscription of Alternaria is emended, and 32 new combinations and 10 new names are proposed. A further 10 names are resurrected, while descriptions are provided for 16 new Alternaria sections.
Collapse
Affiliation(s)
- J H C Woudenberg
- CBS-KNAW Fungal Biodiversity Centre, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands ; Wageningen University and Research Centre (WUR), Laboratory of Phytopathology, Droevendaalsesteeg 1, 6708 PB Wageningen, The Netherlands
| | | | | | | |
Collapse
|
35
|
Kollert F, Binder M, Probst C, Uhl M, Zirlik A, Kayser G, Voll R, Peter HH, Zissel G, Prasse A, Warnatz K. THU0423 CCL18 – a potential biomarker of fibro-inflammatory activity in chronic periaortitis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Ciecko-Michalska I, Binder M, Wyczesany M, Szewczyk J, Senderecka M, Wojcik J, Dziedzic T, Slowik A, Mach T. Electrophysiological correlates of attentional processes in patients with liver cirrhosis without minimal or clinically-overt hepatic encephalopathy. J Physiol Pharmacol 2012; 63:339-346. [PMID: 23070082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/23/2011] [Accepted: 06/21/2012] [Indexed: 06/01/2023]
Abstract
Liver cirrhosis is often accompanied by a spectrum of cognitive deficits, labelled hepatic encephalopathy (HE). The precise specification of cognitive impairment associated with HE has not been yet elucidated. The aim of this study was an attempt to examine cortical function in cirrhotic patients using EEG event-related potentials during a demanding task involving selective attention. We compared group of 30 patients with liver cirrhosis without minimal or overt HE with education-, age- and sex-matched 29 non-cirrhotic controls. Both groups performed an attentional blink (AB) task, which requires detecting and identifying two target characters in a longer series of rapidly and sequentially presented characters. EEG signals from 32 electrodes were measured and then analyzed in the paradigm of event-related potentials (ERP). Though the groups did not differ in the detection rate of the target stimuli, ERP waveforms revealed two group differences of component amplitudes. The first difference was related to the waveform amplitude within the 200-400 ms after first target in the right frontal region (frontocentral N2 component). Moreover, in patient group this amplitude positively correlated with the blood plasma level of alkaline phosphatase and gamma-glutamyl transpeptidase. The second amplitude difference was observed in the midline parieto-occipital regions within the 400-600 ms after the first target (P3b component). The AB task and ERP analysis allowed to find differences in cortical functioning in cirrhotic patients even without overt cognitive deficits. Our finding demonstrates that liver dysfunction can influence cortical processing associated with detecting and categorizing stimulus change.
Collapse
Affiliation(s)
- I Ciecko-Michalska
- Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Cracow, Poland.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Ciecko-Michalska I, Wojcik J, Wyczesany M, Binder M, Szewczyk J, Senderecka M, Dziedzic T, Slowik A, Mach T. Cognitive evoked response potentials in patients with liver cirrhosis without diagnosis of minimal or overt hepatic encephalopathy. A pilot study. J Physiol Pharmacol 2012; 63:271-276. [PMID: 22791641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/22/2011] [Accepted: 06/18/2012] [Indexed: 06/01/2023]
Abstract
Liver cirrhosis is often accompanied by cognitive deficits called minimal hepatic encephalopathy (MHE) when it is observed to a moderate extent. In the present study, brain activity and cognitive functioning were examined in patients with liver cirrhosis without MHE or overt clinical hepatic encephalopathy. A battery of neuropsychological tests and event related potentials (ERPs) were used. Moreover, an additional n-back task was administered with two difficulty levels (1- and 2-back). This task was designed to engage cognitive processes of storage and manipulation of information in working memory. The participants have to decide whether the letter shown was the same as a target (congruence condition). No significant differences were found in the performance of either the neuropsychological tests or the n-back task. However, the expected effects of decreased performance as well as a decrease in P3 amplitude with difficulty level were identified. The interaction of group x congruence condition was also observed in the P2 component time window. These results may indicate group differences manifesting in early stages of information processing in working memory. It confirms that the patients whose neuropsychological performance is within the normal range can still reveal subtle changes in CNS functioning visible in ERP research. The study confirms the usability of the ERP method in diagnosis of neurocognitive functions in patients with liver cirrhosis, which seems to be more sensitive than neuropsychological tests.
Collapse
Affiliation(s)
- I Ciecko-Michalska
- Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Cracow, Poland
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U. Evaluation of BM cytomorphology after allo-SCT in patients with AML. Bone Marrow Transplant 2012; 47:1538-44. [DOI: 10.1038/bmt.2012.70] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
39
|
Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass JO, Walker UA, Peter HH, Warnatz K. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 2011; 71:311-2. [PMID: 21859695 DOI: 10.1136/annrheumdis-2011-200148] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Danzer M, Polin H, Pröll J, Haunschmid R, Hofer K, Stabentheiner S, Hackl C, Kasparu H, König J, Hauser H, Binder M, Weiss R, Gabriel C, Krieger O. Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation. Transplantation 2009; 88:528-32. [PMID: 19696636 DOI: 10.1097/tp.0b013e3181b0e79e] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Hematopoietic stem-cell transplantation is a well-established treatment in various hematologic malignancies, but the outcome depends on disease relapse, infections, and the development and severity of acute and chronic graft-versus-host disease. Some evidence has revealed an important role for the nonclassical major histocompatibility complex class I molecules in transplantation, most notably human leukocyte antigen (HLA)-E. This study evaluates the impact of HLA-E alleles on transplantation outcome after HLA-matched allogeneic HSCT. METHODS We genotyped DNA for HLA-E polymorphism from 83 recipients and their respective donors by real-time polymerase chain reaction after melting curve analysis and compared the results with clinical outcome. RESULTS HLA-E*0103 homozygous patients showed a higher probability of overall survival (P=0.003) and disease-free survival (P=0.001) in a univariate model. Cox regression analysis confirmed HLA-E*0103, 0103 (P=0.006; relative risk 1.12; 95% confidence interval 0.31-1.94) and early stage of disease (P=0.005; relative risk 1.16; 95% confidence interval 0.45-1.86) as independent factors improving overall survival. Moreover, homozygosity for HLA-E*0103 was associated with a significant decreased incidence of transplant-related mortality (P=0.01). CONCLUSIONS We found an association between HLA-E*0103 homozygosity and the significant reduction of transplant-related mortality in related and unrelated HSCT. The risk of posttransplant complications was significantly reduced when the donor possesses the HLA-E*0103, 0103 genotype, and this was translated in a better overall survival.
Collapse
Affiliation(s)
- Martin Danzer
- Red Cross Transfusion Service of Upper Austria, Linz, Austria.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Skibbe O, Binder M, Otto A, Pucci A. Erratum: “Electronic contributions to infrared spectra of adsorbate molecules on metal surfaces: Ethene on Cu(1 1 1)” [J. Chem. Phys. 128, 194703 (2008)]. J Chem Phys 2008. [DOI: 10.1063/1.2992046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
43
|
Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, Streubel B, Muellauer L, Der-Petrossian M, Jonak C, Binder M, Raderer M. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2008; 20:326-30. [PMID: 18836086 DOI: 10.1093/annonc/mdn636] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND We have carried out a retrospective analysis to evaluate the therapeutic value of the anti-CD20 antibody rituximab in 16 consecutive patients with primary cutaneous CD20+ B-cell lymphomas. PATIENTS AND METHODS Sixteen patients (4 females, 12 males) with a median age of 54 years received systemic therapy with rituximab 375 mg/m(2) once weekly for four or six consecutive weeks. Eleven patients had primary cutaneous follicle center cell lymphoma and five patients had a primary cutaneous marginal zone B-cell lymphoma. RESULTS Of the 16 patients with PCBCL, 14 patients (87.5%) achieved complete remission (CR). In two patients, partial remission was obtained and additional focal radiotherapy was applied, which resulted in final CR. Five to 14 (35%) patients with CR relapsed, in an interval between 6 and 37 months. There were no severe side-effects. CONCLUSIONS On the basis of our results, single-agent treatment with i.v. rituximab appears to be feasible and safe and results in a high rate of durable remissions. Judging from our data, it appears to be an attractive treatment option and should be directly compared with local radiotherapy.
Collapse
Affiliation(s)
- J Valencak
- Department of Dermatology, Medical University of Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Egger M, Binder M, Wewalka F, Dieplinger B, Kastler M, Lenz K. [An unusual cause of severe abdominal pain]. Z Gastroenterol 2008; 46:876-9. [PMID: 18810673 DOI: 10.1055/s-2008-1027152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
A 33-year-old previously healthy man was admitted to the hospital with a 6-day history of diffuse abdominal pain and constipation. He was afebrile, looked unwell with a pale skin and displayed an elevated blood pressure. He had no peritoneal sign, and bowel sounds were normal. Blood tests were remarkable for a hematocrit of 26 % and mean cell volume of 83 fl, bilirubin levels were slightly elevated. Abdominal radiographs, abdominal ultrasound and computed tomography showed stool throughout the colon with a non-specific bowel gas pattern. Moreover, colonoscopy and gastroscopy provided no information on the underlying cause of the patient's severe pain. He was treated with fluids and spasmolytic drugs until the result of the urinary porphyrin level was received, which showed an elevated concentration of 1608 microg/d. Consequently, the plasma lead concentration was determined showing an elevated level of 92.3 microg/d. The examination of blood slides revealed erythrocytes with basophile stippling. On physical examination, a bluish discoloration could be seen along the gums. After starting the detoxication therapy with DMPS - 1800 mg p. o. for the first two days followed by 600 mg DMPS daily - the complaints disappeared. In spite of an extensive anamnestic exploration the source of the lead intoxication could not be found until now.
Collapse
Affiliation(s)
- M Egger
- Interne Abteilung, Konventhospital Barmherzige Brüder, Seilersttte 2, 4020 Linz.
| | | | | | | | | | | |
Collapse
|
45
|
Platzbecker U, Binder M, Schmid C, Rutt C, Ehninger G, Bornhauser M. Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation. Haematologica 2008; 93:1276-8. [DOI: 10.3324/haematol.12798] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
46
|
Skibbe O, Binder M, Otto A, Pucci A. Electronic contributions to infrared spectra of adsorbate molecules on metal surfaces: Ethene on Cu(1 1 1). J Chem Phys 2008; 128:194703. [DOI: 10.1063/1.2912186] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Aguilo E, Ahn SH, Ahsan M, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Ancu LS, Andeen T, Anderson S, Andrieu B, Anzelc MS, Arnoud Y, Arov M, Askew A, Asman B, Assis Jesus ACS, Atramentov O, Autermann C, Avila C, Ay C, Badaud F, Baden A, Bagby L, Baldin B, Bandurin DV, Banerjee P, Banerjee S, Barberis E, Barfuss AF, Bargassa P, Baringer P, Barreto J, Bartlett JF, Bassler U, Bauer D, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Bellavance A, Benitez JA, Beri SB, Bernardi G, Bernhard R, Berntzon L, Bertram I, Besançon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Binder M, Biscarat C, Blazey G, Blekman F, Blessing S, Bloch D, Bloom K, Boehnlein A, Boline D, Bolton TA, Borissov G, Bos K, Bose T, Brandt A, Brock R, Brooijmans G, Bross A, Brown D, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burke S, Burnett TH, Busato E, Buszello CP, Butler JM, Calfayan P, Calvet S, Cammin J, Caron S, Carvalho W, Casey BCK, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan K, Chan KM, Chandra A, Charles F, Cheu E, Chevallier F, Cho DK, Choi S, Choudhary B, Christofek L, Christoudias T, Cihangir S, Claes D, Clément B, Clément C, Coadou Y, Cooke M, Cooper WE, Corcoran M, Couderc F, Cousinou MC, Crépé-Renaudin S, Cutts D, Cwiok M, da Motta H, Das A, Davies G, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Degenhardt JD, Déliot F, Demarteau M, Demina R, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Dominguez A, Dong H, Dudko LV, Duflot L, Dugad SR, Duggan D, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Ellison J, Elvira VD, Enari Y, Eno S, Ermolov P, Evans H, Evdokimov A, Evdokimov VN, Ferapontov AV, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Ford M, Fortner M, Fox H, Fu S, Fuess S, Gadfort T, Galea CF, Gallas E, Galyaev E, Garcia C, Garcia-Bellido A, Gavrilov V, Gay P, Geist W, Gelé D, Gerber CE, Gershtein Y, Gillberg D, Ginther G, Gollub N, Gómez B, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Gregores EM, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grünendahl S, Grünewald MW, Guo F, Guo J, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haefner P, Hagopian S, Haley J, Hall I, Hall RE, Han L, Hanagaki K, Hansson P, Harder K, Harel A, Harrington R, Hauptman JM, Hauser R, Hays J, Hebbeker T, Hedin D, Hegeman JG, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hoeth H, Hohlfeld M, Hong SJ, Hooper R, Houben P, Hu Y, Hubacek Z, Hynek V, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jakobs K, Jarvis C, Jesik R, Johns K, Johnson C, Johnson M, Jonckheere A, Jonsson P, Juste A, Käfer D, Kahn S, Kajfasz E, Kalinin AM, Kalk JM, Kalk JR, Kappler S, Karmanov D, Kasper J, Kasper P, Katsanos I, Kau D, Kaur R, Kaushik V, Kehoe R, Kermiche S, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YM, Khatidze D, Kim H, Kim TJ, Kirby MH, Klima B, Kohli JM, Konrath JP, Kopal M, Korablev VM, Kotcher J, Kothari B, Koubarovsky A, Kozelov AV, Krop D, Kryemadhi A, Kuhl T, Kumar A, Kunori S, Kupco A, Kurca T, Kvita J, Lam D, Lammers S, Landsberg G, Lazoflores J, Lebrun P, Lee WM, Leflat A, Lehner F, Lesne V, Leveque J, Lewis P, Li J, Li L, Li QZ, Lietti SM, Lima JGR, Lincoln D, Linnemann J, Lipaev VV, Lipton R, Liu Z, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Love P, Lubatti HJ, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magass C, Magerkurth A, Makovec N, Mal PK, Malbouisson HB, Malik S, Malyshev VL, Mao HS, Maravin Y, Martin B, McCarthy R, Melnitchouk A, Mendes A, Mendoza L, Mercadante PG, Merkin M, Merritt KW, Meyer A, Meyer J, Michaut M, Miettinen H, Millet T, Mitrevski J, Molina J, Mommsen RK, Mondal NK, Monk J, Moore RW, Moulik T, Muanza GS, Mulders M, Mulhearn M, Mundal O, Mundim L, Nagy E, Naimuddin M, Narain M, Naumann NA, Neal HA, Negret JP, Neustroev P, Nilsen H, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, O'Dell V, O'Neil DC, Obrant G, Ochando C, Oguri V, Oliveira N, Onoprienko D, Oshima N, Osta J, Otec R, Otero y Garzón GJ, Owen M, Padley P, Pangilinan M, Parashar N, Park SJ, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Pawloski G, Perea PM, Peters K, Peters Y, Pétroff P, Petteni M, Piegaia R, Piper J, Pleier MA, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pol ME, Pompos A, Pope BG, Popov AV, Potter C, Prado da Silva WL, Prosper HB, Protopopescu S, Qian J, Quadt A, Quinn B, Rangel MS, Rani KJ, Ranjan K, Ratoff PN, Renkel P, Reucroft S, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Robinson S, Rodrigues RF, Royon C, Rubinov P, Ruchti R, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schaile D, Schamberger RD, Scheglov Y, Schellman H, Schieferdecker P, Schmitt C, Schwanenberger C, Schwartzman A, Schwienhorst R, Sekaric J, Sengupta S, Severini H, Shabalina E, Shamim M, Shary V, Shchukin AA, Shivpuri RK, Shpakov D, Siccardi V, Sidwell RA, Simak V, Sirotenko V, Skubic P, Slattery P, Smirnov D, Smith RP, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Sonnenschein L, Sopczak A, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stark J, Steele J, Stolin V, Stoyanova DA, Strandberg J, Strandberg S, Strang MA, Strauss M, Ströhmer R, Strom D, Strovink M, Stutte L, Sumowidagdo S, Svoisky P, Sznajder A, Talby M, Tamburello P, Tanasijczuk A, Taylor W, Telford P, Temple J, Tiller B, Tissandier F, Titov M, Tokmenin VV, Tomoto M, Toole T, Torchiani I, Trefzger T, Trincaz-Duvoid S, Tsybychev D, Tuchming B, Tully C, Tuts PM, Unalan R, Uvarov L, Uvarov S, Uzunyan S, Vachon B, van den Berg PJ, van Eijk B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vartapetian A, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vint P, Vlimant JR, Von Toerne E, Voutilainen M, Vreeswijk M, Wahl HD, Walder J, Wang L, Wang MHLS, Warchol J, Watts G, Wayne M, Weber G, Weber M, Weerts H, Wenger A, Wermes N, Wetstein M, White A, Wicke D, Wilson GW, Wimpenny SJ, Wobisch M, Wood DR, Wyatt TR, Xie Y, Yacoob S, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yip K, Yoo HD, Youn SW, Yu C, Yu J, Yurkewicz A, Zatserklyaniy A, Zeitnitz C, Zhang D, Zhao T, Zhou B, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG. Study of the decay Bs(0)-->Ds(*)Ds(*). Phys Rev Lett 2007; 99:241801. [PMID: 18233437 DOI: 10.1103/physrevlett.99.241801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2007] [Indexed: 05/25/2023]
Abstract
We report a study of the decay Bs(0)-->Ds(*)Ds(*) using a data sample corresponding to 1.3 fb(-1) of integrated luminosity collected by the D0 experiment in 2002-2006 during run II of the Fermilab Tevatron collider. One Ds(*) meson was partially reconstructed in the decay Ds-->phi mu nu, and the other Ds(*) meson was identified using the decay Ds-->phi pi where no attempt was made to distinguish Ds and Ds(*) states. For the branching fraction Br(Bs(0)-->Ds(*)Ds(*)) we obtain a 90% C.L. range [0.002,0.080] and central value 0.039(-0.017)(+0.019)(stat)(-0.015)(+0.016)(syst). This was subsequently used to make the most precise estimate of the width difference DeltaGamma(s)CP in the Bs(0)-Bs(0) system: DeltaGamma(s)CP/Gamma(s)=0.079(-0.035)(+0.038)(stat)(-0.030)(+0.031)(syst).
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Aguilo E, Ahn SH, Ahsan M, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Ancu LS, Andeen T, Anderson S, Andrieu B, Anzelc MS, Arnoud Y, Arov M, Askew A, Asman B, Assis Jesus ACS, Atramentov O, Autermann C, Avila C, Ay C, Badaud F, Baden A, Bagby L, Baldin B, Bandurin DV, Banerjee P, Banerjee S, Barberis E, Barfuss AF, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Bellavance A, Benitez JA, Beri SB, Bernardi G, Bernhard R, Berntzon L, Bertram I, Besançon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Binder M, Biscarat C, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Bloom K, Boehnlein A, Boline D, Bolton TA, Boos EE, Borissov G, Bos K, Bose T, Brandt A, Brock R, Brooijmans G, Bross A, Brown D, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Bunichev V, Burdin S, Burke S, Burnett TH, Busato E, Buszello CP, Butler JM, Calfayan P, Calvet S, Cammin J, Caron S, Carvalho W, Casey BCK, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan K, Chan KM, Chandra A, Charles F, Cheu E, Chevallier F, Cho DK, Choi S, Choudhary B, Christofek L, Christoudias T, Claes D, Clément B, Clément C, Coadou Y, Cooke M, Cooper WE, Corcoran M, Couderc F, Cousinou MC, Cox B, Crépé-Renaudin S, Cutts D, Cwiok M, da Motta H, Das A, Davies B, Davies G, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Degenhardt JD, Déliot F, Demarteau M, Demina R, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dominguez A, Dong H, Dudko LV, Duflot L, Dugad SR, Duggan D, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Ellison J, Elvira VD, Enari Y, Eno S, Ermolov P, Evans H, Evdokimov A, Evdokimov VN, Ferapontov AV, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Ford M, Fortner M, Fox H, Fu S, Fuess S, Gadfort T, Galea CF, Gallas E, Galyaev E, Garcia C, Garcia-Bellido A, Gavrilov V, Gay P, Geist W, Gelé D, Gerber CE, Gershtein Y, Gillberg D, Ginther G, Gollub N, Gómez B, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Gregores EM, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grünendahl S, Grünewald MW, Guo F, Guo J, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haefner P, Hagopian S, Haley J, Hall I, Hall RE, Han L, Hanagaki K, Hansson P, Harder K, Harel A, Harrington R, Hauptman JM, Hauser R, Hays J, Hebbeker T, Hedin D, Hegeman JG, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hoeth H, Hohlfeld M, Hong SJ, Hooper R, Houben P, Hu Y, Hubacek Z, Hynek V, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jakobs K, Jarvis C, Jenkins A, Jesik R, Johns K, Johnson C, Johnson M, Jonckheere A, Jonsson P, Juste A, Käfer D, Kahn S, Kajfasz E, Kalinin AM, Kalk JM, Kalk JR, Kappler S, Karmanov D, Kasper J, Kasper P, Katsanos I, Kau D, Kaur R, Kehoe R, Kermiche S, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YM, Khatidze D, Kim H, Kim TJ, Kirby MH, Klima B, Kohli JM, Konrath JP, Kopal M, Korablev VM, Kotcher J, Kothari B, Koubarovsky A, Kozelov AV, Krop D, Kryemadhi A, Kuhl T, Kumar A, Kunori S, Kupco A, Kurca T, Kvita J, Lam D, Lammers S, Landsberg G, Lazoflores J, Lebrun P, Lee WM, Leflat A, Lehner F, Lesne V, Leveque J, Lewis P, Li J, Li L, Li QZ, Lietti SM, Lima JGR, Lincoln D, Linnemann J, Lipaev VV, Lipton R, Liu Z, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Love P, Lubatti HJ, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magass C, Magerkurth A, Makovec N, Mal PK, Malbouisson HB, Malik S, Malyshev VL, Mao HS, Maravin Y, Martin B, McCarthy R, Melnitchouk A, Mendes A, Mendoza L, Mercadante PG, Merkin M, Merritt KW, Meyer A, Meyer J, Michaut M, Miettinen H, Millet T, Mitrevski J, Molina J, Mommsen RK, Mondal NK, Monk J, Moore RW, Moulik T, Muanza GS, Mulders M, Mulhearn M, Mundal O, Mundim L, Nagy E, Naimuddin M, Narain M, Naumann NA, Neal HA, Negret JP, Neustroev P, Nilsen H, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, O'Dell V, O'Neil DC, Obrant G, Ochando C, Oguri V, Oliveira N, Onoprienko D, Oshima N, Osta J, Otec R, Otero Y Garzón GJ, Owen M, Padley P, Pangilinan M, Parashar N, Park SJ, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Pawloski G, Perea PM, Perfilov M, Peters K, Peters Y, Pétroff P, Petteni M, Piegaia R, Piper J, Pleier MA, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pol ME, Pompos A, Pope BG, Popov AV, Potter C, Prado da Silva WL, Prosper HB, Protopopescu S, Qian J, Quadt A, Quinn B, Rangel MS, Rani KJ, Ranjan K, Ratoff PN, Renkel P, Reucroft S, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Robinson S, Rodrigues RF, Royon C, Rubinov P, Ruchti R, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schaile D, Schamberger RD, Scheglov Y, Schellman H, Schieferdecker P, Schmitt C, Schwanenberger C, Schwartzman A, Schwienhorst R, Sekaric J, Sengupta S, Severini H, Shabalina E, Shamim M, Shary V, Shchukin AA, Shivpuri RK, Shpakov D, Siccardi V, Sidwell RA, Simak V, Sirotenko V, Skubic P, Slattery P, Smirnov D, Smith RP, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Sonnenschein L, Sopczak A, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stark J, Steele J, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strandberg S, Strang MA, Strauss M, Ströhmer R, Strom D, Strovink M, Stutte L, Sumowidagdo S, Svoisky P, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tiller B, Tissandier F, Titov M, Tokmenin VV, Tomoto M, Toole T, Torchiani I, Trefzger T, Trincaz-Duvoid S, Tsybychev D, Tuchming B, Tully C, Tuts PM, Unalan R, Uvarov L, Uvarov S, Uzunyan S, Vachon B, van den Berg PJ, van Eijk B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vartapetian A, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vint P, Vlimant JR, Von Toerne E, Voutilainen M, Vreeswijk M, Wahl HD, Wang L, Wang MHLS, Warchol J, Watts G, Wayne M, Weber G, Weber M, Weerts H, Wenger A, Wermes N, Wetstein M, White A, Wicke D, Wilson GW, Wimpenny SJ, Wobisch M, Wood DR, Wyatt TR, Xie Y, Yacoob S, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yip K, Yoo HD, Youn SW, Yu C, Yu J, Yurkewicz A, Zatserklyaniy A, Zeitnitz C, Zhang D, Zhao T, Zhou B, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG. Search for production of single top quarks via tcg and tug flavor-changing-neutral-current couplings. Phys Rev Lett 2007; 99:191802. [PMID: 18233063 DOI: 10.1103/physrevlett.99.191802] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2007] [Indexed: 05/25/2023]
Abstract
We search for the production of single top quarks via flavor-changing-neutral-current couplings of a gluon to the top quark and a charm (c) or up (u) quark. We analyze 230 pb{-1} of lepton+jets data from pp[over] collisions at a center of mass energy of 1.96 TeV collected by the D0 detector at the Fermilab Tevatron Collider. We observe no significant deviation from standard model predictions, and hence set upper limits on the anomalous coupling parameters kappa{g}{c}/Lambda and kappa{g}{u}/Lambda, where kappa{g} define the strength of tcg and tug couplings, and Lambda defines the scale of new physics. The limits at 95% C.L. are kappa{g}{c}/Lambda<0.15 TeV-1 and kappa{g}{u}/Lambda<0.037 TeV-1.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Platzbecker U, Mohr B, von Bonin M, Binder M, Schetelig J, Ehninger G, Bornhäuser M. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 2007; 21:2384-5. [PMID: 17581611 DOI: 10.1038/sj.leu.2404811] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
50
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Aguilo E, Ahn SH, Ahsan M, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Ancu LS, Andeen T, Anderson S, Andrieu B, Anzelc MS, Arnoud Y, Arov M, Askew A, Asman B, Assis Jesus ACS, Atramentov O, Autermann C, Avila C, Ay C, Badaud F, Baden A, Bagby L, Baldin B, Bandurin DV, Banerjee P, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Bellavance A, Benitez JA, Beri SB, Bernardi G, Bernhard R, Berntzon L, Bertram I, Besançon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Binder M, Biscarat C, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Bloom K, Boehnlein A, Boline D, Bolton TA, Borissov G, Bos K, Bose T, Brandt A, Brock R, Brooijmans G, Bross A, Brown D, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burke S, Burnett TH, Busato E, Buszello CP, Butler JM, Calfayan P, Calvet S, Cammin J, Caron S, Carvalho W, Casey BCK, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Charles F, Cheu E, Chevallier F, Cho DK, Choi S, Choudhary B, Christofek L, Claes D, Clément B, Clément C, Coadou Y, Cooke M, Cooper WE, Corcoran M, Couderc F, Cousinou MC, Cox B, Crépé-Renaudin S, Cutts D, Cwiok M, da Motta H, Das A, Das M, Davies B, Davies G, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Degenhardt JD, Déliot F, Demarteau M, Demina R, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dominguez A, Dong H, Dudko LV, Duflot L, Dugad SR, Duggan D, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Ellison J, Elvira VD, Enari Y, Eno S, Ermolov P, Evans H, Evdokimov A, Evdokimov VN, Feligioni L, Ferapontov AV, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Ford M, Fortner M, Fox H, Fu S, Fuess S, Gadfort T, Galea CF, Gallas E, Galyaev E, Garcia C, Garcia-Bellido A, Gavrilov V, Gay A, Gay P, Geist W, Gelé D, Gelhaus R, Gerber CE, Gershtein Y, Gillberg D, Ginther G, Gollub N, Gómez B, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Gregores EM, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grünendahl S, Grünewald MW, Guo F, Guo J, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haefner P, Hagopian S, Haley J, Hall I, Hall RE, Han L, Hanagaki K, Hansson P, Harder K, Harel A, Harrington R, Hauptman JM, Hauser R, Hays J, Hebbeker T, Hedin D, Hegeman JG, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hoeth H, Hohlfeld M, Hong SJ, Hooper R, Houben P, Hu Y, Hubacek Z, Hynek V, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jakobs K, Jarvis C, Jenkins A, Jesik R, Johns K, Johnson C, Johnson M, Jonckheere A, Jonsson P, Juste A, Käfer D, Kahn S, Kajfasz E, Kalinin AM, Kalk JM, Kalk JR, Kappler S, Karmanov D, Kasper J, Kasper P, Katsanos I, Kau D, Kaur R, Kehoe R, Kermiche S, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YM, Khatidze D, Kim H, Kim TJ, Kirby MH, Klima B, Kohli JM, Konrath JP, Kopal M, Korablev VM, Kotcher J, Kothari B, Koubarovsky A, Kozelov AV, Krop D, Kryemadhi A, Kuhl T, Kumar A, Kunori S, Kupco A, Kurca T, Kvita J, Lam D, Lammers S, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee WM, Leflat A, Lehner F, Lesne V, Leveque J, Lewis P, Li J, Li L, Li QZ, Lietti SM, Lima JGR, Lincoln D, Linnemann J, Lipaev VV, Lipton R, Liu Z, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Love P, Lubatti HJ, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magass C, Magerkurth A, Makovec N, Mal PK, Malbouisson HB, Malik S, Malyshev VL, Mao HS, Maravin Y, McCarthy R, Melnitchouk A, Mendes A, Mendoza L, Mercadante PG, Merkin M, Merritt KW, Meyer A, Meyer J, Michaut M, Miettinen H, Millet T, Mitrevski J, Molina J, Mommsen RK, Mondal NK, Monk J, Moore RW, Moulik T, Muanza GS, Mulders M, Mulhearn M, Mundal O, Mundim L, Nagy E, Naimuddin M, Narain M, Naumann NA, Neal HA, Negret JP, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, O'Dell V, O'Neil DC, Obrant G, Ochando C, Oguri V, Oliveira N, Onoprienko D, Oshima N, Osta J, Otec R, Otero Y Garzón GJ, Owen M, Padley P, Pangilinan M, Parashar N, Park SJ, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Pawloski G, Perea PM, Peters K, Peters Y, Pétroff P, Petteni M, Piegaia R, Piper J, Pleier MA, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pol ME, Pompos A, Pope BG, Popov AV, Potter C, Prado da Silva WL, Prosper HB, Protopopescu S, Qian J, Quadt A, Quinn B, Rangel MS, Rani KJ, Ranjan K, Ratoff PN, Renkel P, Reucroft S, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Robinson S, Rodrigues RF, Royon C, Rubinov P, Ruchti R, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schaile D, Schamberger RD, Scheglov Y, Schellman H, Schieferdecker P, Schmitt C, Schwanenberger C, Schwartzman A, Schwienhorst R, Sekaric J, Sengupta S, Severini H, Shabalina E, Shamim M, Shary V, Shchukin AA, Shivpuri RK, Shpakov D, Siccardi V, Sidwell RA, Simak V, Sirotenko V, Skubic P, Slattery P, Smith RP, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Sonnenschein L, Sopczak A, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stark J, Steele J, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strandberg S, Strang MA, Strauss M, Ströhmer R, Strom D, Strovink M, Stutte L, Sumowidagdo S, Svoisky P, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tiller B, Titov M, Tokmenin VV, Tomoto M, Toole T, Torchiani I, Trefzger T, Trincaz-Duvoid S, Tsybychev D, Tuchming B, Tully C, Tuts PM, Unalan R, Uvarov L, Uvarov S, Uzunyan S, Vachon B, van den Berg PJ, van Eijk B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vartapetian A, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vint P, Vlimant JR, Von Toerne E, Voutilainen M, Vreeswijk M, Wahl HD, Wang L, Wang MHLS, Warchol J, Watts G, Wayne M, Weber G, Weber M, Weerts H, Wermes N, Wetstein M, White A, Wicke D, Wilson GW, Wimpenny SJ, Wobisch M, Womersley J, Wood DR, Wyatt TR, Xie Y, Yacoob S, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yip K, Yoo HD, Youn SW, Yu C, Yu J, Yurkewicz A, Zatserklyaniy A, Zeitnitz C, Zhang D, Zhao T, Zhou B, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG. Search for techniparticles in e+jets events at D0. Phys Rev Lett 2007; 98:221801. [PMID: 17677833 DOI: 10.1103/physrevlett.98.221801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2006] [Indexed: 05/16/2023]
Abstract
We search for the technicolor process pp-->rhoT/omegaT-->WpiT in events containing one electron and two jets, in data corresponding to an integrated luminosity of 390 pb(-1), recorded by the D0 experiment at the Fermilab Tevatron. Technicolor predicts that technipions pi(T) decay dominantly into bb, bc, or bc, depending on their charge. In these events b and c quarks are identified by their secondary decay vertices within jets. Two analysis methods based on topological variables are presented. Since no excess above the standard model prediction was found, the result is presented as an exclusion in the pi(T) vs rho(T) mass plane for a given set of model parameters.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|